AGOURON/VERTEX HEPATITIS C PROTEASE DISCOVERIES PROVE INFECTIOUS TO INVESTORS
Executive Summary
Agouron's and Vertex' experience with HIV protease inhibitor research has Wall Street enthusiastic that the companies will be able to develop drugs attacking a similar mechanism in hepatitis C virus infection